Related Experiment Video

Updated: Jun 21, 2026

On-Chip Endothelial Inflammatory Phenotyping
12:43

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation

Paul M Ridker1

  • 1Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA. pridker@partners.org

Journal of Thrombosis and Haemostasis : JTH
|July 28, 2009
PubMed

Insights

The Cardiovascular Inflammation Reduction Trial (CIRT) investigates if low-dose methotrexate can prevent vascular events in patients with high-sensitivity C-reactive protein (hsCRP). This study tests if reducing inflammation directly impacts cardiovascular outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Research
  • Clinical Trials

Background:

  • Inflammation is a key factor in atherothrombosis, with elevated high-sensitivity C-reactive protein (hsCRP) indicating increased vascular risk.
  • Previous trials like JUPITER showed statins reduce cardiovascular events in individuals with low cholesterol and high hsCRP.
  • A direct test of the inflammatory hypothesis requires an anti-inflammatory agent without confounding effects on atherothrombosis.

Purpose of the Study:

  • To directly test the inflammatory hypothesis of atherothrombosis.
  • To determine if very-low-dose-methotrexate (VLDM) reduces vascular event rates in patients with stable coronary artery disease and elevated hsCRP.
  • To evaluate VLDM as a novel therapeutic approach for cardiovascular disease prevention.

Main Methods:

  • The Cardiovascular Inflammation Reduction Trial (CIRT) is a large-scale clinical trial.
  • It involves 7000 patients with stable coronary artery disease and persistently elevated hsCRP.
  • Participants are randomized to receive either placebo or very-low-dose-methotrexate (10 mg weekly).

Main Results:

  • This section is not applicable as the abstract describes a proposed trial and not its results.
  • The abstract does not contain specific findings or data from the CIRT trial.
  • The JUPITER trial is mentioned as a related study, showing statin benefits.

Conclusions:

  • The CIRT trial aims to confirm the inflammatory hypothesis of atherothrombosis.
  • If successful, the trial could establish VLDM as a treatment for cardiovascular disorders.
  • This research may open new avenues for preventing and treating cardiovascular diseases by targeting inflammation.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Inflammation01:38

Inflammation

Overview
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...